AV
AVNS
—
NYSE
Medical Equipment & Supplies
Avanos Medical, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,2B USD
P/E
—
EV / Rev
1,6x
Div yield
—
Op margin
-8,8 %
ROE
-9,3 %
Net margin
-10,4 %
Debt / equity
0,01
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Avanos Medical designs and manufactures medical devices focused on specialty nutrition systems and pain management and recovery solutions.
Business. Avanos Medical designs and manufactures medical devices focused on specialty nutrition systems and pain management and recovery solutions.
Classification70 %
SectorHealthcare
Business sectorHealthcare Equipment & Supplies
Industry groupMedical Equipment, Supplies & Distribution
IndustryMedical Equipment & Supplies
ActivityMedical Devices
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
T. Rowe Price Investment Management, Inc.
largest disclosed fund holder
Profitability→
-9,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to AVNS. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Avanos Medical designs and manufactures medical devices focused on specialty nutrition systems and pain management and recovery solutions.
Classification70 %
SectorHealthcare
Business sectorHealthcare Equipment & Supplies
Industry groupMedical Equipment, Supplies & Distribution
IndustryMedical Equipment & Supplies
ActivityMedical Devices
AI synthesis
GENERATEDAvanos Medical maintains a conservative capital structure with a debt-to-equity ratio of 0.01 and a current ratio of 2.48, indicating strong short-term liquidity coverage. The balance sheet holds $65.6 million in cash and equivalents against $10.9 million in short-term debt, resulting in a net cash position. However, the company generated negative operating cash flow of -$12.3 million in Q1 2026, suggesting working capital consumption or timing mismatches despite the healthy balance sheet metrics. The market capitalization stands at $1.19 billion, trading at a price-to-book ratio of 4.34.
Profitability metrics show significant pressure, with a return on equity of -9.32% and a return on assets of -6.94%. The company reported net income of $5.1 million on revenue of $182.2 million in Q1 2026, yielding a net margin of approximately 2.8%. Operating income was $8.9 million, indicating that while the core business generates positive operating leverage, non-operating items or tax effects may be impacting the bottom line. The negative EV/EBITDA of -49.88 reflects the current earnings volatility or one-time charges impacting EBITDA calculations.
The company operates through two primary segments: Specialty Nutrition Systems and Pain Management and Recovery. Revenue concentration risk is present, with filings noting customer concentration risks involving two major customers. Geographic exposure includes significant operations in the United States, with manufacturing concentration in Mexico noted as a key operational risk factor. The company also holds international operations in Canada, Japan, Belgium, and the UK, though specific revenue splits are not detailed in the snapshot.
Growth trajectory analysis is limited by the absence of historical period data in the input. However, the current quarter revenue of $182.2 million provides a baseline for annualized projections. The company has undergone recent restructuring initiatives and divestitures, including the sale of its RH business for $110 million in cash, which impacts the comparability of historical revenue streams. The pending merger with affiliates of American Industrial Partners introduces uncertainty regarding future growth vectors and strategic direction.
Risk factors include medium dilution risk, as indicated by the difference between basic shares (46.7 million) and diluted shares (47.5 million), suggesting outstanding options or convertible instruments. Key flags highlight potential dilution or offering risks. Operational risks include supply chain disruptions, inflationary pressures, and the concentration of manufacturing in Mexico. Regulatory risks involve changes in reimbursement policies from government healthcare programs and private insurers, which could adversely affect product demand and pricing.
Recent events include critical 8-K filings indicating material agreements, changes in control, or other significant corporate actions. The company faces risks related to the pending merger with American Industrial Partners, including the potential failure to complete the transaction on anticipated terms. Filings also disclose risks associated with cybersecurity threats, geopolitical conflicts, and tariff impacts on imported raw materials. The company continues to execute on restructuring initiatives aimed at improving operational efficiency and cost structure.
Key takeaways
- Strong liquidity position with $65.6M cash and 2.48 current ratio, but negative operating cash flow of -$12.3M in Q1 2026.
- Negative returns on equity (-9.32%) and assets (-6.94%) signal profitability challenges despite positive operating income.
- Medium dilution risk exists with 830k additional diluted shares, alongside key flags for potential offering risks.
- Strategic uncertainty looms due to the pending merger with American Industrial Partners and recent RH business divestiture.
- Operational risks are concentrated in Mexican manufacturing and exposure to healthcare reimbursement policy changes.
- Customer concentration risk is present with two major customers accounting for significant receivables.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Revenue $182.2M; Operating income $8.9M.
Revenue$182.2M
Operating income$8.9M
Net income$5.1M
Free cash flow—
EPS—
Operating cash flow-$12.3M
Financials
Income statement
Revenue$182.2M
Gross profit$94.2M
Operating income$8.9M
Net income$5.1M
Margins
Gross margin51.7%
Operating margin4.9%
Net margin2.8%
FCF margin—
Balance sheet
Total assets$1.05B
Total liabilities$268.0M
Total equity$782.1M
Cash & equivalents$65.6M
Long-term debt—
Cash flow
Operating cash flow-$12.3M
CapEx—
Free cash flow—
SBC$3.7M
P&L flow · revenue → net income
Highlights
- ▍Revenue $182.2M
- ▍Operating income $8.9M
- ▍Net margin 2.8%
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Revenue $520.3M; Operating income -$64.1M.
Revenue$520.3M
Operating income-$64.1M
Net income-$71.6M
Free cash flow—
EPS—
Operating cash flow$46.5M
Financials
Income statement
Revenue$520.3M
Gross profit$267.9M
Operating income-$64.1M
Net income-$71.6M
Margins
Gross margin51.5%
Operating margin-12.3%
Net margin-13.8%
FCF margin—
Balance sheet
Total assets$1.07B
Total liabilities$289.7M
Total equity$778.0M
Cash & equivalents$70.5M
Long-term debt—
Cash flow
Operating cash flow$46.5M
CapEx—
Free cash flow—
SBC$11.4M
P&L flow · revenue → net income
Highlights
- ▍Revenue $520.3M
- ▍Operating income -$64.1M
- ▍Net margin -13.8%
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Revenue $342.5M; Operating income -$64.2M.
Revenue$342.5M
Operating income-$64.2M
Net income-$70.2M
Free cash flow—
EPS—
Operating cash flow$32.5M
Financials
Income statement
Revenue$342.5M
Gross profit$181.9M
Operating income-$64.2M
Net income-$70.2M
Margins
Gross margin53.1%
Operating margin-18.7%
Net margin-20.5%
FCF margin—
Balance sheet
Total assets$1.04B
Total liabilities$262.7M
Total equity$776.3M
Cash & equivalents$90.3M
Long-term debt—
Cash flow
Operating cash flow$32.5M
CapEx—
Free cash flow—
SBC$7.9M
P&L flow · revenue → net income
Highlights
- ▍Revenue $342.5M
- ▍Operating income -$64.2M
- ▍Net margin -20.5%
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Revenue $701.2M; Operating income -$61.6M.
Revenue$701.2M
Operating income-$61.6M
Net income-$72.9M
Free cash flow—
EPS—
Operating cash flow$74.7M
Financials
Income statement
Revenue$701.2M
Gross profit$353.9M
Operating income-$61.6M
Net income-$72.9M
Margins
Gross margin50.5%
Operating margin-8.8%
Net margin-10.4%
FCF margin—
Balance sheet
Total assets$1.07B
Total liabilities$295.5M
Total equity$778.2M
Cash & equivalents$89.8M
Long-term debt—
Cash flow
Operating cash flow$74.7M
CapEx—
Free cash flow—
SBC$12.6M
P&L flow · revenue → net income
Highlights
- ▍Revenue $701.2M
- ▍Operating income -$61.6M
- ▍Net margin -10.4%
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Revenue $687.8M; Operating income -$396.2M.
Revenue$687.8M
Operating income-$396.2M
Net income-$392.1M
Free cash flow—
EPS—
Operating cash flow$100.7M
Financials
Income statement
Revenue$687.8M
Gross profit$381.3M
Operating income-$396.2M
Net income-$392.1M
Margins
Gross margin55.4%
Operating margin-57.6%
Net margin-57.0%
FCF margin—
Balance sheet
Total assets$1.15B
Total liabilities$325.7M
Total equity$828.5M
Cash & equivalents$107.7M
Long-term debt—
Cash flow
Operating cash flow$100.7M
CapEx—
Free cash flow—
SBC$13.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $687.8M
- ▍Operating income -$396.2M
- ▍Net margin -57.0%
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Revenue $687.8M; Operating income -$396.2M.
Revenue$687.8M
Operating income-$396.2M
Net income-$392.1M
Free cash flow—
EPS—
Operating cash flow$100.7M
Financials
Income statement
Revenue$687.8M
Gross profit$381.3M
Operating income-$396.2M
Net income-$392.1M
Margins
Gross margin55.4%
Operating margin-57.6%
Net margin-57.0%
FCF margin—
Balance sheet
Total assets$1.15B
Total liabilities$325.7M
Total equity$828.5M
Cash & equivalents$107.7M
Long-term debt—
Cash flow
Operating cash flow$100.7M
CapEx—
Free cash flow—
SBC$13.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $687.8M
- ▍Operating income -$396.2M
- ▍Net margin -57.0%
ANNUALFiled 2023-12-31
FY 2023 · Full-year highlights
Revenue $673.3M; Operating income $4.2M.
Revenue$673.3M
Operating income$4.2M
Net income-$61.8M
Free cash flow—
EPS—
Operating cash flow$32.4M
Financials
Income statement
Revenue$673.3M
Gross profit$379.7M
Operating income$4.2M
Net income-$61.8M
Margins
Gross margin56.4%
Operating margin0.6%
Net margin-9.2%
FCF margin—
Balance sheet
Total assets$1.69B
Total liabilities$456.1M
Total equity$1.24B
Cash & equivalents$87.7M
Long-term debt—
Cash flow
Operating cash flow$32.4M
CapEx—
Free cash flow—
SBC$15.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $673.3M
- ▍Operating income $4.2M
- ▍Net margin -9.2%
ANNUALFiled 2023-12-31
FY 2024 · Full-year highlights
Revenue $673.3M; Operating income $4.2M.
Revenue$673.3M
Operating income$4.2M
Net income-$61.8M
Free cash flow—
EPS—
Operating cash flow$32.4M
Financials
Income statement
Revenue$673.3M
Gross profit$379.7M
Operating income$4.2M
Net income-$61.8M
Margins
Gross margin56.4%
Operating margin0.6%
Net margin-9.2%
FCF margin—
Balance sheet
Total assets$1.69B
Total liabilities$456.1M
Total equity$1.24B
Cash & equivalents$87.7M
Long-term debt—
Cash flow
Operating cash flow$32.4M
CapEx—
Free cash flow—
SBC$15.8M
P&L flow · revenue → net income
Highlights
- ▍Revenue $673.3M
- ▍Operating income $4.2M
- ▍Net margin -9.2%
Valuation FY
Market price
$24,99
Market cap
$1.19B
Enterprise valueⓘ
$1.13B
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
1.6x
EV / Op incomeⓘ
—
EV / OCFⓘ
15.2x
P / Bⓘ
4.3x
P / Tangible bookⓘ
4.3x
Tangible book
$273.4M
Net cashⓘ
$54.7M
Current ratioⓘ
2.5
Debt / equityⓘ
0.0
ROAⓘ
-6.9%
ROEⓘ
-9.3%
Cash conversionⓘ
-102.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
1.8%
Dilution ratioⓘ
1.8%
Revenue by segment
Business relationships
Business relationships4 disclosed relationships · 1 type · extracted from filings & disclosures
Customers4
Mckesson CorpMCK.OCustomer100%Source ↗
ANON:CUST:AVNS.O:MeANON:CUST:AVNS.O:MeCustomer88%Source ↗
ANON:CUST:AVNS.O:MedlineIndustriesANON:CUST:AVNS.O:MedlineIndustriesCustomer88%Source ↗
ANON:CUST:AVNS.O:OwensMinorIncANON:CUST:AVNS.O:OwensMinorIncCustomer88%Source ↗
Supply chain
Vendors → AVNS ↔ Partners → Customers · click any node to drill
4 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 1,00 |
| Revenue | —no estimate | —no estimate | 710,0M USD |
| Operating income | —no estimate | —no estimate | 68,0M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Corporate eventM&A horizon
M&A probabilityconf 3 %
Probability
3 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-25 · 1,0× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-07-29
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution1 analysts
Strong buy0
Buy0
Hold1
Sell0
Strong sell0
Operating income · consensus68,0M USD
EPS surprise
−6,1 %
reported vs consensus · miss
Revenue surprise
−1,2 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskMedium
Liquidity riskLow
Filing-based flags
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Op Margin-8,8 %Below median
Net Margin-10,4 %Below median
ROE-9,3 %Above median
D/E0,01Below median
Cash Conv-1,02Bottom quartile
Corporate actions / M&A
M&A probabilityconf —
Probability
3 %
Base rate
3 %
Band
Low
180-day horizon · target 2027-01-25 · 1,0× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 42 952 sh8 grants8 insiders
- Director · Restricted Share Units → Common StockDisposed 12 003disposition · 2026-07-27
- Director · Restricted Share Units → Common StockDisposed 12 003disposition · 2026-07-27
- Director · Restricted Share Units → Common StockDisposed 12 003disposition · 2026-07-27
- SVP, Operations · Employee Stock Option (right to buy) → Common StockDisposed 37 520 @ $13,69disposition · 2026-07-27
- Chief Executive Officer · Employee Stock Option (right to buy) → Common StockDisposed 239 354 @ $13,69disposition · 2026-07-27
- SVP, Chief Financial Officer · Employee Stock Option (right to buy) → Common StockDisposed 21 038 @ $15,24disposition · 2026-07-27
- SVP, Chief Financial Officer · Employee Stock Option (right to buy) → Common StockDisposed 69 630 @ $13,69disposition · 2026-07-27
- SVP, Operations · Employee Stock Option (right to buy) → Common StockDisposed 21 914 @ $15,24disposition · 2026-07-27
- Director · Restricted Share Units → Common StockDisposed 12 003disposition · 2026-07-27
- Director · Restricted Share Units → Common StockDisposed 12 003disposition · 2026-07-27
- Director · Restricted Share Units → Common StockAcquired 12 003grant · 2026-05-08
- Director · Restricted Share Units → Common StockAcquired 12 003grant · 2026-05-08
- Director · Restricted Share Units → Common StockAcquired 12 003grant · 2026-05-08
- Director · Restricted Share Units → Common StockAcquired 12 003grant · 2026-05-08
- Director · Restricted Share Units → Common StockAcquired 12 003grant · 2026-05-08
- SVP, Operations · Employee Stock Option (right to buy) → Common StockAcquired 37 520 @ $13,69grant · 2026-03-13
- Chief Executive Officer · Employee Stock Option (right to buy) → Common StockAcquired 239 354 @ $13,69grant · 2026-03-13
- SVP, Chief Financial Officer · Employee Stock Option (right to buy) → Common StockAcquired 69 630 @ $13,69grant · 2026-03-13
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- AVANOS MEDICAL, INC. company facts · 2026-08-01
- AVANOS MEDICAL, INC. 10-Q 2026-05-05 · 2026-08-01
- AVANOS MEDICAL, INC. 10-K 2026-02-24 · 2026-08-01
- AVANOS MEDICAL, INC. 10-Q 2025-11-05 · 2026-08-01
- AVANOS MEDICAL, INC. 10-Q 2025-08-05 · 2026-08-01
- 8-K (sec_8k_material) on AVNS · 2026-08-01
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,05 %$0M
- Investment Managers · as of 2026-03-310,01 %$29M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2024-06-300,00 %$140M
- Investment Managers · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$28M
- Investment Managers · as of 2026-03-310,00 %$15M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2026-03-310,00 %$7M
- Institutional Investor · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2024-12-310,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$40M
- Funds · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net buying2 buys · 4 sellsnet $494K10 insiders · last 365d
- Chief Executive Officer · Common StockOther 444 730 @ $25,00$11,1M · 2026-07-27
- SVP, Operations · Common StockOther 55 741 @ $25,00$1,4M · 2026-07-27
- SVP, Operations · Common StockOther 54 886 · 2026-07-27
- SVP, Operations · Common StockOther 54 886 @ $25,00$1,4M · 2026-07-27
- SVP, Chief Financial Officer · Common StockOther 135 596 @ $25,00$3,4M · 2026-07-27
- SVP, Chief Financial Officer · Common StockOther 96 121 · 2026-07-27
- SVP, Chief Financial Officer · Common StockOther 96 121 @ $25,00$2,4M · 2026-07-27
- Chief Executive Officer · Common StockOther 322 194 @ $25,00$8,1M · 2026-07-27
- Chief Executive Officer · Common StockOther 444 730 · 2026-07-27
- Director · Common StockOther 50 090 @ $25,00$1,3M · 2026-07-27
- Director · Common StockOther 54 640 @ $25,00$1,4M · 2026-07-27
- Director · Common StockOther 4 817 @ $25,00$120K · 2026-07-27
- Director · Common StockOther 13 811 @ $25,00$345K · 2026-07-27
- Director · Common StockOther 40 000 @ $25,00$1,0M · 2026-07-27
- Director · Common StockOther 79 590 @ $25,00$2,0M · 2026-07-27
- SVP, Operations · Common StockOther 4 264 @ $24,64$105K · 2026-04-22
- SVP, Chief Financial Officer · Common StockOther 4 228 @ $24,64$104K · 2026-04-22
- Chief Executive Officer · Common StockOther 21 194 @ $14,53$308K · 2026-04-14
- SVP, Chief Financial Officer · Common StockOther 29 481 · 2026-03-13
- Principal Accounting Officer · Common StockOther 2 211 · 2026-03-13
- Chief Executive Officer · Common StockOther 101 341 · 2026-03-13
- SVP, Operations · Common StockOther 15 886 · 2026-03-13
- SVP, Chief Financial Officer · Common StockOther 1 119 @ $13,29$15K · 2026-03-09
- Principal Accounting Officer · Common StockOther 226 @ $13,29$3K · 2026-03-09
- SVP, Chief Financial Officer · Common StockOther 5 907 @ $13,79$81K · 2026-03-06
Short positioning
1.8Mshares short-1.3% vs prior
2.35days to cover
74.3%short of daily vol
11fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
AVNSCanonical
NYSE · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskMedium
Liquidity riskLow
Source documents mention dilution or offering risk.
Relationship graph
This companySectorCustomers
Evidence & claims
From filings & derived data- Operating cash flow (annual): USD 74.7MUnknown
- Gross profit (annual): USD 353.9MUnknown
- EPS (basic) (annual): USD-PER-SHARES -2Unknown
- Cost of revenue (annual): USD 347.3MUnknown
- Cash & equivalents (annual): USD 89.8MUnknown
- Shareholders' equity (annual): USD 778.2MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -2Unknown
- Pre-tax income (annual): USD -66.2MUnknown
- Shares outstanding (annual): 46.46MUnknown
- Net income (annual): USD -72.9MUnknown
- Operating income (annual): USD -61.6MUnknown
- Long-term debt (annual): USD 90.3MUnknown
- Revenue (annual): USD 701.2MUnknown
- R&D expense (annual): USD 23.3MUnknown
- Current liabilities (annual): USD 165.2MUnknown
- Total assets (annual): USD 1.07BUnknown
- Total liabilities (annual): USD 295.5MUnknown
- Current assets (annual): USD 355.4MUnknown
- Current assets (annual): USD 393.4MUnknown
- Shareholders' equity (annual): USD 828.5MUnknown
- Total liabilities (annual): USD 325.7MUnknown
- Long-term debt (annual): USD 125.3MUnknown
- Net income (annual): USD -392.1MUnknown
- EPS (basic) (annual): USD-PER-SHARES -9Unknown
Showing 24 of 36 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-31 04:36 UTCFILINGMaterial 8-K
2026-07-27INSIDERDelgado Sigfrido transacted 54.9k sh — SVP, Operations
2026-07-27INSIDERBLACKFORD GARY transacted 79.6k sh — Director ~$1.99M
2026-07-27INSIDERBLACKFORD GARY transacted 40.0k sh — Director ~$1.00M
2026-07-27INSIDEREgbuonu-Davis Lisa transacted 13.8k sh — Director ~$345k
2026-07-27INSIDERFranchini Indrani Lall transacted 4.8k sh — Director ~$120k
2026-07-27INSIDEROLEARY PATRICK J transacted 54.6k sh — Director ~$1.37M
2026-07-27INSIDERShimer Julie Ann transacted 50.1k sh — Director ~$1.25M
2026-07-27INSIDERPacitti David transacted 444.7k sh — Chief Executive Officer ~$11.12M
2026-07-27INSIDERPacitti David transacted 322.2k sh — Chief Executive Officer ~$8.05M
2026-07-27INSIDERGalovan Scott Michael transacted 96.1k sh — SVP, Chief Financial Officer ~$2.40M
2026-07-27INSIDERGalovan Scott Michael transacted 135.6k sh — SVP, Chief Financial Officer ~$3.39M
2026-07-27INSIDERDelgado Sigfrido transacted 55.7k sh — SVP, Operations ~$1.39M
2026-07-27INSIDERBLACKFORD GARY disposed of 12.0k sh Restricted Share Units — Director
2026-07-27INSIDEREgbuonu-Davis Lisa disposed of 12.0k sh Restricted Share Units — Director
2026-07-27INSIDERGalovan Scott Michael disposed of 69.6k sh Employee Stock Option (right to buy) — SVP, Chief Financial Officer
2026-07-27INSIDERGalovan Scott Michael disposed of 21.0k sh Employee Stock Option (right to buy) — SVP, Chief Financial Officer
2026-07-27INSIDERDelgado Sigfrido disposed of 21.9k sh Employee Stock Option (right to buy) — SVP, Operations
2026-07-27INSIDERDelgado Sigfrido disposed of 37.5k sh Employee Stock Option (right to buy) — SVP, Operations
2026-07-27INSIDERShimer Julie Ann disposed of 12.0k sh Restricted Share Units — Director
2026-07-27INSIDERPacitti David disposed of 239.4k sh Employee Stock Option (right to buy) — Chief Executive Officer
2026-07-27INSIDEROLEARY PATRICK J disposed of 12.0k sh Restricted Share Units — Director
2026-07-27INSIDERFranchini Indrani Lall disposed of 12.0k sh Restricted Share Units — Director
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-30 03:14 UTCHOLDERInstitutional holding changed
2026-06-30 03:14 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-27 03:14 UTCHOLDERInstitutional holding changed
2026-06-27 03:14 UTCHOLDER1 institutional position change flagged (1 major)
2026-05-08 00:00 UTCINSIDER5 insider transactions — 2026-05 5 derivative
2026-05-08INSIDERFranchini Indrani Lall acquired 12.0k sh Restricted Share Units — Director
2026-05-08INSIDEROLEARY PATRICK J acquired 12.0k sh Restricted Share Units — Director
2026-05-08INSIDERShimer Julie Ann acquired 12.0k sh Restricted Share Units — Director
2026-05-08INSIDERBLACKFORD GARY acquired 12.0k sh Restricted Share Units — Director
2026-05-08INSIDEREgbuonu-Davis Lisa acquired 12.0k sh Restricted Share Units — Director
2026-04-22 00:00 UTCINSIDER3 insider transactions — 2026-04 · net sell $517k
2026-04-22INSIDERDelgado Sigfrido transacted 4.3k sh — SVP, Operations ~$105k
2026-04-22INSIDERGalovan Scott Michael transacted 4.2k sh — SVP, Chief Financial Officer ~$104k
Showing the 40 most recent of 71 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage